On April 18, 2018 Kymab Group Limited ("Kymab"), a biopharmaceutical company developing fully human monoclonal antibody therapeutics, reported data on KY1044 (a novel anti-ICOS antibody) and KY1055 (a novel ICOS/PD-L1 bispecific antibody), at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual meeting held April 14-18, 2018 in Chicago, Illinois, USA (Press release, Kymab, APR 18, 2018, View Source [SID1234537006]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) Annual Meeting covers the latest basic, translational, clinical, and prevention-focused research in the field, including important areas such as early detection, cancer interception, and survivorship in all populations.
Notes to Editors
About Kymab’s AACR (Free AACR Whitepaper) Posters
KY1044 poster
Title: The combination of immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response (#2792)
Session Title: Therapeutic Antibodies, Including Engineered Antibodies 2
Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM
Link to the Poster (1.4 Mb PDF)
KY1055 poster
Title: KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. (#LB-153)
Session Title: Late-Breaking Research: Clinical Research 1
Session Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM